Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
- Status
- WITHDRAWN
- Phase
- PHASE1
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
- Status
- COMPLETED
- Phase
- PHASE3
Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)
- Status
- TERMINATED
- Phase
- PHASE1
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study
- Status
- UNKNOWN
- Phase
- PHASE4
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)
- Status
- COMPLETED
- Phase
- PHASE3
Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Transplanting Hepatitis C Lungs Into Negative Lung Recipients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation
- Status
- TERMINATED
- Phase
- PHASE4
Prevalence of Chronic Thromboembolic Pulmonary Hypertension After Acute Pulmonary Embolism : (Preva-CTEPH)
- Status
- COMPLETED
- Phase
- NA
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
- Status
- RECRUITING
- Phase
- PHASE4
Identifying Improvements in an ED Elder Friendly Area Based on Patient Experience (EDEFA_TheirVoice Project)
- Status
- UNKNOWN
- Phase
- N/A
Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)
- Status
- COMPLETED
- Phase
- PHASE4
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Status
- COMPLETED
- Phase
- PHASE3